Navigation Links
U-M Receives NIH, FDA Grant To Study Adaptive Clinical Trial Design
Date:10/7/2010

ANN ARBOR, Mich., Oct. 7 /PRNewswire-USNewswire/ -- Clinical trials in which participants are randomly assigned to different treatments by design are the cornerstone of clinical research. When conducted correctly, it's widely accepted by the research community that the results are valid and can be trusted.  

But researchers at the University of Michigan hope to improve the process for bringing therapies and medical devices to patients by investigating the impact of a class of innovative trial designs known as adaptive clinical trials – which make adjustments to the trial using information accumulated as patients are enrolled – in hopes of improving the efficiency of clinical trials as a whole.

"One of the hard and firm rules of randomized clinical trials, and for good reason, is you can't just go changing your trial to get the results you want," says William Barsan, M.D., chair and director of the U-M Department of Emergency Medicine.  "But with adaptive clinical trials, you spend a lot of time up-front asking yourself, 'What if?' so that any changes made throughout the course of the study are all agreed upon at the beginning, written into the study design and only changed throughout the course of the study based on pre-specified rules."

Researchers cannot always predict at what point a specific drug or treatment will show therapeutic results during the course of the study, if at all. Once a standard trial is underway, trial characteristics such as inclusion criteria cannot be modified or changed even if a sufficient amount of data collected before the trials end-date demonstrates that such changes may be necessary.

For example, remaining patients who are randomized to the placebo group cannot benefit from the therapeutic effect of the treatment, and money will continue to be spent until the trial ends. Current trials often include periodic review of data to search for early benefit or early harm but changes are
'/>"/>

SOURCE University of Michigan Health System
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
2. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
3. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
4. Abbott Receives Supplemental FDA Approval for its Best-in-Class in Sensitivity RealTime HIV-1 Viral Load Test
5. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
6. CryoCor Receives FDA Approval for Right Atrial Flutter
7. Ranbaxy Receives Approval to Manufacture and Market Hydrocodone Bitartrate and Acetaminophen Tablets USP
8. Dimericine(R) Receives FDA Fast Track Designation for Treatment Of Photosensitivity in XP Patients
9. Poniard Pharmaceuticals Receives FDA Fast Track Designation for Picoplatin for Treatment of Small Cell Lung Cancer
10. Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma
11. The Female Health Company Receives USAID DELIVER PROJECT Order for 5 Million Units
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... CHAPEL HILL, N.C. , July 31, 2015 ... to product success in the biopharmaceutical market. Patients ... the process of selecting and switching therapies. This ... and is pushing marketers, efforts toward patient-focused marketing. ... to patient engagement, marketers have learned it,s important ...
(Date:7/31/2015)... 2015  In today,s ever-changing marketplace, call centers must ... increasingly connected, and increasingly impatient with slow service. The ... channels and tools is driving call centers to explore ... According to research by benchmarking firm, Best Practices, ... in a call center study realize the impact of ...
(Date:7/31/2015)... NEW YORK , July 31, 2015  Seeger Weiss ... Drug Administration (FDA) issued a warning letter to C.R. Bard, ... for not taking adequate strides to correct violations the agency ... aware of these violations after the FDA cited them during ... 05, 2015, in Bard,s Tempe, AZ , ...
Breaking Medicine Technology:Consumers Forcing Pharmaceutical Industry to Shift its Marketing Focus from Products to Patients 2Best Practices in Building World-Class Consumer & Over-the-Counter Call Centers 2Seeger Weiss LLP Reports That The FDA Has Issued A Warning Letter To IVC Filter Manufacturer, C.R. Bard 2Seeger Weiss LLP Reports That The FDA Has Issued A Warning Letter To IVC Filter Manufacturer, C.R. Bard 3
... , ... PTC Therapeutics, Inc. (PTC) today announced the initiation of an ... men with nonsense mutation Duchenne/ Becker muscular dystrophy (nmDBMD) ... trial is evaluating the best methods for measuring functional abilities ...
... , , OXFORD, England , ... focused on allergy, today announced that it has,initiated phase II ... cat allergies. With the start of these studies, and the ... company,now has three clinical development programmes in phase II. Each ...
Cached Medicine Technology:PTC Therapeutics Announces Additional Study of Ataluren in Patients with Advanced Nonsense Mutation Duchenne/Becker Muscular Dystrophy 2PTC Therapeutics Announces Additional Study of Ataluren in Patients with Advanced Nonsense Mutation Duchenne/Becker Muscular Dystrophy 3PTC Therapeutics Announces Additional Study of Ataluren in Patients with Advanced Nonsense Mutation Duchenne/Becker Muscular Dystrophy 4PTC Therapeutics Announces Additional Study of Ataluren in Patients with Advanced Nonsense Mutation Duchenne/Becker Muscular Dystrophy 5PTC Therapeutics Announces Additional Study of Ataluren in Patients with Advanced Nonsense Mutation Duchenne/Becker Muscular Dystrophy 6Circassia Extends its Clinical-Stage Portfolio With Phase II Trials of T-Cell Vaccines Against House Dust Mite and Cat Allergies 2Circassia Extends its Clinical-Stage Portfolio With Phase II Trials of T-Cell Vaccines Against House Dust Mite and Cat Allergies 3
(Date:8/1/2015)... ... August 01, 2015 , ... The condition where veins are enlarged and ... often causing pain and discomfort. Those who spend a lot of time on their ... Vein Center is doing what it can to create awareness and provide a cure ...
(Date:8/1/2015)... ... August 01, 2015 , ... Calvary Hospital today announced that it ... Bronx campus. The goal is to bring this Torah – dating from 1880 – ... rituals and religious services. , Scroll No. 515, from the town of Taus-Domazlice, ...
(Date:8/1/2015)... ... ... Tina Wilcoxson, owner of Freeport Maine’s Royal River Natural Foods, was named one ... Federation, the largest retail trade association in the world, for her “advocacy and engagement” ... named as such. According to the NRF’s website, Retail Champions are “Main Street business ...
(Date:8/1/2015)... ... ... Brig and Lita Hart, icons of the network marketing industry and founders of ... the HOPE Movement of EvolvHealth. In what has been a long-term relationship between the ... their missions of purpose together to change the course of the network marketing industry. ...
(Date:8/1/2015)... CT (PRWEB) , ... August 01, 2015 , ... ... Point Partners I, L.P. (“GPP”) portfolio company has acquired Premier Physical Therapy & ... it into its portfolio of state-of-the-art clinics. , “Our acquisition of Premier Physical ...
Breaking Medicine News(10 mins):Health News:Northeast Houston Vein Center Warns Men about Varicose Veins 2Health News:Northeast Houston Vein Center Warns Men about Varicose Veins 3Health News:Calvary Hospital Announces Plans to Restore Historic Torah 2Health News:Calvary Hospital Announces Plans to Restore Historic Torah 3Health News:Local Retail Advocate Wins National Recognition 2Health News:Looking for HOPE? Healthy Home Has Evolv’d 2Health News:Looking for HOPE? Healthy Home Has Evolv’d 3Health News:Professional Physical Therapy Now Largest Outpatient Physical Therapy Provider in Northeast With Acquisition of Premier Physical Therapy & Wellness 2
... supporters will discuss implications of federal health-reform bills at the ... at 9:00 am. Health-policy experts will examine which proposed legislation ... will make sure Americans are not forced to have a ... cradle to grave and that citizens are not forced to ...
... Pa., June 17 The GBS/CIDP Foundation International, ... afflicted with Guillain-Barre Syndrome (GBS), Chronic Inflammatory Demyelinating ... Patricia A. Bryant to the position of Executive ... succeeds Estelle L. Benson, who along with her ...
... (June 17, 2009) Two new studies published by ... demonstrate a need for more vigilant monitoring for seizure ... subtle seizures that are typically unrecognized. These subtle seizures ... damage, death and severe disability. Published in recent ...
... A $4.15 million, four-year National Institutes of Health grant ... Medicine to conduct the first health study of teenage ... Dennis Fortenberry, M.D., M.S., professor of pediatrics in the ... follow 72 males, ages 14-17 years, for three years. ...
... , CiNet Acquires Industry-Leading Training Assets to Help ... Workplace Efficiency , , DALLAS, June 17 ... emerging eLearning company serving customers across the public ... the formal launch of its business operations. ...
... also guards against infection, study shows , WEDNESDAY, June ... development of emphysema also defends the lungs against bacterial ... thought that the only thing macrophage elastase, matrix metalloproteinase-12 ... the tissue destruction seen in emphysema patients. , "But ...
Cached Medicine News:Health News:GBS/CIDP Foundation International Appoints Patricia A. Bryant as Executive Director 2Health News:New findings encourage more vigilant monitoring of seizure activity among intensive care patients 2Health News:New findings encourage more vigilant monitoring of seizure activity among intensive care patients 3Health News:Cellular telephones to expand knowledge of health behaviors and microorganisms in adolescent males 2Health News:Critical Information Network (CiNet(TM)) Launches to Provide eLearning Solutions to Public Safety, Healthcare and Industrial Operations Professionals 2Health News:Critical Information Network (CiNet(TM)) Launches to Provide eLearning Solutions to Public Safety, Healthcare and Industrial Operations Professionals 3Health News:Lung Enzyme Both Friend and Foe 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: